News
Read all about our latest news.
Stratified neuroscience company Monument Therapeutics announces first clinical study of MT1980, a novel treatment for neuroinflammation, has successfully met all objectives
Monument Therapeutics presents positive preclinical data for cognitive impairment in schizophrenia programme at BAP conference
Contact Us
We believe that neuroscience will be in the next decade what oncology has been in the last.
